Healthcare Global Enterprises Ltd

- Next 2-3 years planned capex: Rs. 600-700 crore - Rs. 300 crore dedicated to maintenance capex - Remaining for upgrading infrastructure, increasing existing capacity, and brownfield expansion - Brownfield expansion to add around 700 beds in markets like Ahmedabad, Vizag, Baroda, Cuttack - Greenfield expansion planned in 10-12 new cities (e.g., Pune, Surat, Varanasi, Kanpur), adding 200-400 beds - Greenfield projects largely funded through internal accruals, maintaining net debt to EBITDA ratio of 2-2.5x - Each new centre's capex approximately Rs. 100 crore depending on market specifics - Focus on cautious, disciplined capital allocation with emphasis on improving existing network efficiency and expanding through targeted market entry

- Overall revenue growth expected to outpace industry, sustaining over 15% per annum. - Average realization improvement targeted at 4% to 5% annually. - Inpatient volume growth anticipated at 9% to 10% in near to midterm. - Incremental revenue growth split: 70%-75% from existing centres, 10%-15% from brownfield expansion, and 8%-10% from greenfield projects. - Existing network has significant growth potential through capacity expansion, addition of clinical teams, specialty mix enhancement, and technology upgrades. - Medium-term goal to realize Rs.4,000 crore revenue potential over 4-5 years from current Rs.2,200 crore at existing price points and optimized utilization. - Network growth driven by deepening clinical presence, expanding clinical domains, improving payor mix, strengthening brand, and scaling international business. - New markets and acquisitions to add approximately 1,000 beds and 10 additional LINACs.

- Revenue growth expected at 15%+ CAGR over medium to long term, outpacing industry growth. - EBITDA expected to grow faster than historical CAGR of 18%, supported by operational efficiencies, improved payor mix, and network optimization. - Mature centers delivering EBITDA margins of 25% pre-corporate cost and ROCE around 27%; company-wide EBITDA margin expected to improve to 21%-22% in near term and higher in the long term. - Incremental revenue largely from existing centers (70%-75%) with expansion via brownfield and greenfield projects adding about 1,000 beds and 10 LINACs. - ROCE expected to be sustainably 20%+ over next five years as more centers mature and profitability improves. - Capex of Rs.600-700 crore planned over 2-3 years, funded mainly through internal accruals to maintain net debt/EBITDA ratio between 2-2.5x.

The provided transcript and content from the Healthcare Global Enterprises Limited earnings call do not mention any details regarding a current or expected order book or pending orders. The discussion primarily revolves around: - Capacity expansion plans (adding 1,000 beds with ~700 beds via brownfield expansion and 200-400 beds via greenfield in select cities). - Capital expenditure plans (Rs.500-600 crore for expansion over next 2-3 years). - Focus on revenue growth, payor mix optimization, and margin improvement over 3-5 years. - Operational metrics, clinical strategy, and network maturity timelines. - No specific information on current or expected order book or pending orders is disclosed in the document.

- The company has conserved capital over the last five years, reducing net debt to EBITDA ratio from 6.2x in FY2020 to about 2.3x in FY2025, showing focus on deleveraging. - Current net debt to EBITDA ratio is comfortable at around 2.5x, with prudent leverage management. - Capex of Rs.600-700 crore planned over the next 2-3 years; funding primarily to come from internal accruals and available borrowing headroom. - The company is evaluating its equity and debt ratio and will take appropriate calls on raising equity or debt at the right time. - For greenfield expansion, internal accruals will be the primary source of capital. - No specific or immediate fundraising announced; future equity or debt raises will be considered as per strategic need.